triapine Report issue

Small molecule Experimental
AACT DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
3-Aminopyridine-2-carboxaldehyde thiosemicarbazone is substance of interest for the treatment of cancer. It is a thiosemicarbazone derivative of 3-aminopyridine-2-carboxaldehyde. It presents an N-N-S array of donor sites that strongly bind iron, robbing iron-containing enzymes of their prosthetic group.   Wikipedia

Chemistry

  • SMILES: NC(=S)N/N=C/c1ncccc1N
  • InChIKey: XMYKNCNAZKMVQN-NYYWCZLTSA-N
  • Mol. Mass: 195.25
  • ALogP: -0.17
  • ChEMBL Molecule:
    triapine  
More Chemistry

Pharmacology

Alternative names

3-aminopyridine-2-carboxaldehyde thiosemicarbazone | 3-apct | nsc 663249 | pan811 | pan 811 | pan-811 | triapine

Organizations (18)

Research & Development (18)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (48)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (48)


 

Breast Neoplasms (Phase 2)

Breast Neoplasms, Male (Phase 2)

Burkitt Lymphoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Endometrial Neoplasms (Early Phase 1)

Esophageal Neoplasms (Phase 2)

Gallbladder Neoplasms (Phase 2)

Hamartoma (Phase 2)

Hodgkin Disease (Phase 1)

Intraocular Lymphoma (Phase 1)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 1)

Leukemia, Eosinophilic, Acute (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia-Lymphoma, Adult T-Cell (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 2)

Leukemia, Myeloid, Chronic-Phase (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 1)

Lymphoma, B-Cell, Marginal Zone (Phase 1)

Lymphoma, Follicular (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Large-Cell, Anaplastic (Phase 1)

Lymphoma, Large-Cell, Immunoblastic (Phase 1)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1)

Lymphoma, T-Cell (Phase 1)

Myelodysplastic-Myeloproliferative Diseases (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Polycythemia Vera (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Primary Myelofibrosis (Phase 2)

Prostatic Neoplasms (Phase 2)

Sezary Syndrome (Phase 1)

Thrombocythemia, Essential (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Vaginal Neoplasms (Phase 2)

Vulvar Neoplasms (Phase 1)

Waldenstrom Macroglobulinemia (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 32
  • # of Trial Organizations: 18

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue